Immunoassay for detection of neurotoxic amino acid associated with neurological disorders
    1.
    发明授权
    Immunoassay for detection of neurotoxic amino acid associated with neurological disorders 有权
    用于检测与神经系统疾病相关的神经毒性氨基酸的免疫测定

    公开(公告)号:US08603753B2

    公开(公告)日:2013-12-10

    申请号:US13056877

    申请日:2009-07-02

    CPC classification number: G01N33/6812 C07K16/44 C07K2317/33

    Abstract: An immunoassay for screening a sample to detect the presence of β-N-methylamino-L-alanine (BMAA) is disclosed. Antibodies specific for BMAA are disclosed. Antibodies that bind to BMAA on immunoblots are disclosed. Immunoassays and kits to detect the presence of BMAA in a sample by contacting the sample with an antibody that binds to BMAA, and detecting the antibody bound to the sample, are disclosed. Immunoassays and kits for screening for the presence of BMAA in a subject by analyzing a tissue sample obtained from the subject to detect the present of BMAA in the tissue sample, where the presence of BMAA in the tissue sample indicates exposure of the subject to an environmental source of BMAA, are disclosed. Immunoassays and kits for detecting an environmental source of BMAA, by screening an environmental sample to detect the presence of BMAA in the sample, wherein the presence of a detectable amount of BMAA in the sample indicates the sample is an environmental source of BMAA, are disclosed.

    Abstract translation: 公开了用于筛选样品以检测β-N-甲基氨基-L-丙氨酸(BMAA)的存在的免疫测定。 公开了针对BMAA的抗体。 公开了在免疫印迹上结合BMAA的抗体。 公开了通过使样品与结合BMAA的抗体接触并检测与样品结合的抗体来检测样品中BMAA存在的免疫测定和试剂盒。 用于通过分析从受试者获得的组织样品来检测受试者中BMAA存在的免疫测定和试剂盒,以检测组织样品中BMAA的存在,其中组织样品中BMAA的存在表明受试者暴露于环境 BMAA的来源被披露。 通过筛选环境样品以检测样品中BMAA的存在来检测BMAA的环境来源的免疫测定和试剂盒,其中样品中可检测量的BMAA的存在表明样品是BMAA的环境来源,公开 。

    Screening for neurotoxic amino acid associated with neurological disorders
    2.
    发明授权
    Screening for neurotoxic amino acid associated with neurological disorders 有权
    筛查与神经系统疾病相关的神经毒性氨基酸

    公开(公告)号:US08541184B2

    公开(公告)日:2013-09-24

    申请号:US13015288

    申请日:2011-01-27

    Abstract: Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of β-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.

    Abstract translation: 公开了筛选神经障碍的方法。 具体地,公开了通过分析从受试者获得的组织样品中存在与神经系统疾病相关的神经毒性氨基酸或神经毒性衍生物的升高水平来筛选受试者神经障碍的方法。 具体地,通过确定获得的组织样品中的β-N-甲基氨基-L-丙氨酸(BMAA)的水平,公开了用于诊断受试者的神经障碍或预测受试者发展神经障碍的可能性的方法 从主题。 公开了与神经障碍相关的环境因素的筛选方法。 公开了抑制,治疗或预防神经障碍的方法。

    DUCTED VERTICAL TAKE-OFF AND LANDING (VTOL) PERSONNEL CARRIER
    3.
    发明申请
    DUCTED VERTICAL TAKE-OFF AND LANDING (VTOL) PERSONNEL CARRIER 审中-公开
    垂直起落架(垂直起落架)人员承运人

    公开(公告)号:US20090224095A1

    公开(公告)日:2009-09-10

    申请号:US12042030

    申请日:2008-03-04

    Abstract: A vertical take-off and landing (VTOL) vehicle includes a first thruster, a first duct, a second thruster, a second duct, an engine pod, and a transport unit. The first duct is configured to direct airflow generated by the first thruster. The second duct is configured to direct airflow generated by the second thruster. The engine pod is formed between the first duct and the second duct. The transport unit is formed between the first duct and the second duct, and is configured to transport a person or another payload. The transport unit is alternatively a person transport or a surveillance package pod.

    Abstract translation: 垂直起降(VTOL)车辆包括第一推进器,第一管道,第二推进器,第二管道,发动机舱和运输单元。 第一管道构造成引导由第一推进器产生的气流。 第二管道构造成引导由第二推进器产生的气流。 发动机舱形成在第一管道和第二管道之间。 传送单元形成在第一管道和第二管道之间,并且被配置为运送人或另一有效载荷。 运输单元是人运输或监视包装盒。

    IMMUNOASSAY FOR DETECTION OF NEUROTOXIC AMINO ACID ASSOCIATED WITH NEUROLOGICAL DISORDERS
    4.
    发明申请
    IMMUNOASSAY FOR DETECTION OF NEUROTOXIC AMINO ACID ASSOCIATED WITH NEUROLOGICAL DISORDERS 有权
    用于检测与神经病变相关的神经毒性氨基酸的免疫测定

    公开(公告)号:US20110223624A1

    公开(公告)日:2011-09-15

    申请号:US13056877

    申请日:2009-07-02

    CPC classification number: G01N33/6812 C07K16/44 C07K2317/33

    Abstract: An immunoassay for screening a sample to detect the presence of β-N-methylamino-L-alanine (BMAA) is disclosed. Antibodies specific for BMAA are disclosed. Antibodies that bind to BMAA on immunoblots are disclosed. Immunoassays and kits to detect the presence of BMAA in a sample by contacting the sample with an antibody that binds to BMAA, and detecting the antibody bound to the sample, are disclosed. Immunoassays and kits for screening for the presence of BMAA in a subject by analyzing a tissue sample obtained from the subject to detect the present of BMAA in the tissue sample, where the presence of BMAA in the tissue sample indicates exposure of the subject to an environmental source of BMAA, are disclosed. Immunoassays and kits for detecting an environmental source of BMAA, by screening an environmental sample to detect the presence of BMAA in the sample, wherein the presence of a detectable amount of BMAA in the sample indicates the sample is an environmental source of BMAA, are disclosed.

    Abstract translation: 公开了用于筛选样品以检测存在β-甲基氨基-L-丙氨酸(BMAA)的免疫测定。 公开了针对BMAA的抗体。 公开了在免疫印迹上结合BMAA的抗体。 公开了通过使样品与结合BMAA的抗体接触并检测与样品结合的抗体来检测样品中BMAA存在的免疫测定和试剂盒。 用于通过分析从受试者获得的组织样品来检测受试者中BMAA存在的免疫测定和试剂盒,以检测组织样品中BMAA的存在,其中组织样品中BMAA的存在表明受试者暴露于环境 BMAA的来源被披露。 通过筛选环境样品以检测样品中BMAA的存在来检测BMAA的环境来源的免疫测定和试剂盒,其中样品中可检测量的BMAA的存在表明样品是BMAA的环境来源,公开 。

Patent Agency Ranking